Pan-Facial Layering of Hyaluronic Acid Filler
NCT07063511
Recruiting
Recent advancements in anatomical studies have enabled a more sophisticated approach to treating patients with facial aesthetic concerns with hyaluronic acid (HA) fillers. For instance, volumizing a specific area of concern may be warranted, but it is essential to understand how the underlying patient anatomy is continuing to laxity and hollowness. Varying manufacturing technology have offered a range of HA fillers with different physical and chemical properties adapted to different indications... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Erevna Innovations Inc., Montreal, Quebec
Conditions: Aesthetic
Register for Updates
Modified Deep Extubation vs. Standard Awake Extubation
NCT06318715
Recruiting
The proposed study is to compare a modified DE technique, which is regularly used for low-risk patients by staff anesthesiologists at our institution, to a standard awake extubation. This modified deep extubation (mDE) occurs while the patient is still anaesthetized but at a lower dose of anaesthetic gas than previously described, and balanced with long acting opioids to attenuate the airway reaction. As previously stated, the literature shows that the risks of DE are equivalent to those of regu... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/03/2025
Locations: Department of Anesthesia Mount Sinai Hospital, Toronto, Ontario
Conditions: Extubation
Register for Updates
Frailty Rehabilitation
NCT03824106
Recruiting
Frailty is an important clinical state that contributes to falls, hospitalization, institutionalization and death. When an individual simultaneously has many health problems, a frailty "tipping point" may be triggered by even a minor stressful event such as adding a new drug or urinary tract infection. Our research suggests that approximately 23% of Canadians over age 65 are frail, and by age 85 this estimate increases to over 40%. As we learn more about frailty and its consequences, there is an... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/03/2025
Locations: McMaster University - St. Peter's Hospital, Hamilton, Ontario
Conditions: Frailty
Register for Updates
Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis
NCT05347238
Recruiting
Fluid-unresponsive hypotension needing cardiotropic drug treatment is a serious complication in very preterm neonates with suspected late-onset sepsis (LOS; defined as culture positive or negative bloodstream infection or necrotizing enterocolitis occurring \>48 hours of age). In Canada, \~250 very preterm neonates receive cardiotropic drugs for LOS related fluid-unresponsive hypotension every year; of these \~35-40% die. Unlike for adult patients, there is little evidence to inform practice. Wh... Read More
Gender:
ALL
Ages:
Between 21 weeks and 32 weeks
Trial Updated:
07/03/2025
Locations: Banner-University Medical Center Phoenix, Phoenix, Arizona +22 locations
Conditions: Late-Onset Neonatal Sepsis, Extreme Prematurity, Neonatal Hypotension
Register for Updates
To Assess Safety of Mitapivat and Provide Proof of Concept of the Efficacy of the Drug in Patients With RBC Membranopathies or CDAII.
NCT07055243
Recruiting
This is a prospective exploratory phase 2 study designed to evaluate the safety and efficacy of mitapivat in RBC membranopathies and CDAII, a rare sub type of anemia. Nine patients from Princess Margaret who are diagnosed with CDAII will be enrolled to the study. Patients will be in the trial for 57 weeks treatment weeks and a safety follow up week after 30 days from last dose. First 8 weeks will be dose escalating period followed by 48 weeks of fixed dose period. 57th week will be dose tapering... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: University Health Network (UHN), Toronto, Ontario
Conditions: Anemia
Register for Updates
Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
NCT05029063
Recruiting
The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Nova Scotia Health, Halifax, Nova Scotia +10 locations
Conditions: Venous Thromboembolism, Cancer
Register for Updates
The Chocolate Almond Study - Relating Chewing to Satiation and Postprandial Response
NCT07065461
Recruiting
The goal of this clinical trial is to relate chewing behaviours to food intake and postprandial response for a texturally complex food matrix (almonds in white chocolate) in healthy young females. The main questions it aims to answer are: * Does the presence or preparation of almonds (whole versus chopped) influence satiation, i.e., the amount consumed at an ad libitum meal? * What is the correlation between chewing behaviour, satiation, and changes in postprandial glucose, triacylglycerols, an... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
07/03/2025
Locations: Department of Human Health Sciences, Guelph, Ontario
Conditions: Satiation, Satiety, Postprandial Glycemia, Postprandial Lipemia
Register for Updates
LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM)
NCT06446739
Recruiting
An estimated 10-15% of critically ill patients with acute kidney failure in the intensive care unit receive acute dialysis therapy. The majority of these patients initially receive a continuous form of dialysis therapy call continuous renal replacement therapy (CRRT). Prior studies have suggested that higher CRRT dose-intensity improved health outcomes for these patients; however, this was not found in high-quality clinical trials. These more recent trials suggested a lower range of dose-intensi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: University of Alberta Hospital, Edmonton, Alberta
Conditions: Acute Kidney Injury, Dialysis; Complications
Register for Updates
Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
NCT05462145
Recruiting
This study will evaluate the safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal or persistent atrial fibrillation (AF).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/03/2025
Locations: University of Alabama Heersink School of Medicine, Birmingham, Alabama +19 locations
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169
Recruiting
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic steatohepatitis \[NASH\]).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/03/2025
Locations: 89bio Clinical Study Site, Birmingham, Alabama +238 locations
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Register for Updates
Optimizing the Management of Staphylococcus Aureus Bacteremia (OPTIMUS-SAB)
NCT06338176
Recruiting
Staphylococcus aureus bacteremia (SAB) is associated with high morbidity and mortality rates with an incidence disproportionately higher in vulnerable populations. Management according to evidence-based care parameters, in particular Infectious Diseases (ID) consultation, is associated with improved mortality. SAB management is suboptimal in Alberta compared to other jurisdictions. An Alberta-based pilot study confirmed that timely recommendations to optimize SAB care, including ID consultation,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Athabasca Healthcare Centre, Athabasca, Alberta +100 locations
Conditions: Staph Aureus Bacteremia
Register for Updates
Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes
NCT06399302
Recruiting
This project aims to collect detailed clinical data, blood samples, and patient-reported outcomes from 2,600 lung transplant candidates, donors, and recipients at Lung Transplant Centers. The goal is to create a robust resource for various research objectives, including studying the impact of variations in donor and medical practices on clinical outcomes. The project also seeks to identify serum biomarkers associated with or predictive of specific post-transplant complications and conditions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: University of California Los Angeles, Los Angeles, California +16 locations
Conditions: Lung Transplant; Complications, Lung Transplant; Infection or Inflammation, Lung Transplant Rejection, Lung Transplant Failure
Register for Updates